Match!
Lillian Werner
Harvard University
CancerPathologyImmunologyProstate cancerMedicine
148Publications
22H-index
2,473Citations
What is this?
Publications 140
Newest
#1Bradley Alexander McGregor (Harvard University)H-Index: 7
#2Rana R. McKayH-Index: 15
Last. Toni K. Choueiri (Harvard University)H-Index: 81
view all 20 authors...
PURPOSEIn this multicenter phase II trial, we evaluated atezolizumab combined with bevacizumab in patients with advanced renal cell carcinoma (RCC) with variant histology or any RCC histology with ...
2 CitationsSource
#1Meredith M. Regan (Harvard University)H-Index: 64
#2Lillian Werner (Harvard University)H-Index: 22
Last. David F. McDermott (Harvard University)H-Index: 73
view all 15 authors...
PURPOSEOutcome measures that comprehensively capture attributes of immuno-oncology agents, including prolonged treatment-free time and persistent treatment-related adverse events (TRAEs), are neede...
1 CitationsSource
#1Jacqueline S. Garcia (Harvard University)H-Index: 8
#2Lillian Werner (Harvard University)H-Index: 22
Last. Robert J. Soiffer (Harvard University)H-Index: 95
view all 36 authors...
1 CitationsSource
#1Richard Stone (Harvard University)H-Index: 96
#2Daniel J. DeAngelo (Harvard University)H-Index: 60
Last. Marlise R. Luskin (Harvard University)H-Index: 13
view all 10 authors...
Source
#1T. A. KnudsenH-Index: 2
#2Vibe SkovH-Index: 9
Last. Ann Mullally (Broad Institute)H-Index: 23
view all 31 authors...
Source
#1Erin Parry (Harvard University)H-Index: 1
Last. Pavan Bachireddy (Harvard University)H-Index: 14
view all 22 authors...
Source
#1Evan C. Chen (Harvard University)H-Index: 6
#2Lillian Werner (Harvard University)H-Index: 22
Last. Andrew M. Brunner (Harvard University)H-Index: 14
view all 7 authors...
Source
#1Jacob D. Soumerai (Harvard University)H-Index: 16
#2Matthew S. Davids (Harvard University)H-Index: 33
Last. Jeremy S. Abramson (Harvard University)H-Index: 46
view all 10 authors...
AbstractBendamustine-rituximab (BR) is a standard therapy in CLL, and lenalidomide has single-agent activity. This phase 1 study evaluated lenalidomide-BR as initial CLL therapy. Thirteen patients ...
Source
#1Meredith M. Regan (Harvard University)H-Index: 64
#2Michael B. Atkins (Georgetown University)H-Index: 76
Last. David F. McDermott (BIDMC: Beth Israel Deaconess Medical Center)H-Index: 73
view all 10 authors...
Abstract Background Conventional measures such as median progression-free survival may suboptimally characterize the full impact of immuno-oncology (I-O) agents vs other systemic anticancer therapies. Patients discontinuing I-O agents may experience periods of disease control without needing subsequent systemic anticancer therapy (Rx) but may still experience toxicity (TOX). Treatment-free survival (TFS) ± TOX can simultaneously characterize disease control and TOX for this off-treatment period....
Source
#1Anis Hamid (Harvard University)H-Index: 2
#2Lillian Werner (Harvard University)H-Index: 22
Last. Christopher Sweeney (Harvard University)H-Index: 57
view all 7 authors...
e16601Background: We previously showed that loss of PTEN by quantitative multiplex immunofluorescence (qIF) is associated with relapse after prostatectomy. Low expression of TTP, which modulates th...
Source
12345678910